Friday, August 14 – Studies show that GLP-1 medications may have positive effects on mental health. Image Credit: Delmaine Donson/Getty

GLP-1 medications are associated with a lower risk of worsening anxiety and depression. 

GLP-1 drugs may help reduce key symptoms of binge eating disorder and “food noise.” 

Other surprising mental health benefits of GLP-1s include reduced impulsivity and violent behaviors. 

Friday, August 14 – New research shows that using a GLP-1 before bariatric surgery may not increase weight loss. coldsnowstorm · E+/Getty

A new study found that using GLP-1 medications, such as Ozempic or Wegovy, before bariatric surgery was not associated with greater weight loss 12 months after the procedure.

Researchers also found no significant differences in diabetes control, postoperative complications, length of hospital stay, or emergency department visits.

Friday, August 14 – A review titled “Integrating Precision Nutrition with GLP-1 Receptor Agonist Therapy: Mechanisms, Clinical Outcomes, and Pharmacoeconomic Implications” examines the biological mechanisms of nutrition, body composition, gut microbiome, inflammation, metabolism and genetics to develop individualized recommendations for optimal treatment with GLP-1 drugs.

Friday, August 14 – (MedPage Today) — Bariatric surgery patients who took GLP-1 medications prior to surgery lost the same amount of weight after 1 year as individuals unexposed to the blockbuster class of drugs, a retrospective review indicated.
Among 383 patients…

Friday, August 14 – UK media are reporting that a 19-year-old American college student died in her dorm room last year after taking a GLP-1 weight loss drug. Court papers show that Josephine Nassar died from a fatal irregular heartbeat triggered in part by the GLP-1 and a heart condition that she apparently had been born with.

Friday, August 14 – Khartis raises oral immunology funds, Neurocrine drug safety concerns, and more biotech news from The Readout

Thursday, August 13 – Ozempic-like drugs appear to weaken more than hunger—they may also reduce cravings for alcohol and other addictive substances. Scientists are increasingly tracing this effect to the lateral septum, a brain region that helps connect memories and surroundings with rewarding experiences. Packed with GLP-1 receptors, it may act as a crucial control point between thinking about a reward and feeling compelled to pursue it. The discovery could open new approaches to treating addiction as well as obesity.

Thursday, August 13 – Beyond the legal action, Eli Lilly is calling on healthcare providers, regulatory authorities, online platforms and even logistics companies to help stem the illegal sale of its next-generation asset for weight loss.

Thursday, August 13 – (MedPage Today) — For the first time ever, U.S. News & World Report has released ratings of telehealth platforms offering GLP-1 weight-loss drugs.
The inaugural ratings evaluated 20 online platforms that offer FDA-approved, brand-name GLP…

Thursday, August 13 – As millions turn to online telehealth platforms to get weight loss drugs, U.S. News and World Report is launching its first-ever official evaluation and ratings of GLP-1 online providers. Gretel Schueller, managing editor of health, joins TODAY to share an exclusive look at the list and discuss best practices to find safe medication online.

Wednesday, August 12 – The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.

Wednesday, August 12 – Recent research has found that the popular GLP-1 medication, Mounjaro, may help lower heart attack risk in people with type 2 diabetes. Galina Zhigalova · Moment/Getty

New research suggests the GLP-1 medication Mounjaro may lower the risk of heart attack and other major cardiovascular events in people with type 2 diabetes and established heart disease.

Wednesday, August 12 – (MedPage Today) — More than 150 deaths possibly linked to injectable weight-loss medications were reported in the U.K., according to government regulators. (The Independent)
Texas Children’s Hospital in Houston will open the nation’s first detransition…

Wednesday, August 12 – (MedPage Today) — GLP-1 drugs, used for type 2 diabetes and weight loss, have been touted for their many benefits, but it’s their side effects that often make headlines, especially those with compelling monikers like “Ozempic teeth.”
Here, we…

Wednesday, August 12 – (MedPage Today) — Shanghai-based biotech company HuidaGene Therapeutics disclosed the death of a child 1 year ago in a trial of an investigational gene-editing therapy for Duchenne muscular dystrophy.
Semaglutide (Wegovy) attenuated a proteomics…

Wednesday, August 12 – Medicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.

Tuesday, August 11 – GLP-1 drugs like Mounjaro may help lower heart attack risk by 33%.

Tuesday, August 11 – For decades, obesity medications produced only modest weight loss. But in recent years, Ozempic and related GLP-1 therapies have transformed the field, enabling sustained weight loss of 10% to 15% or more. Despite their success, however, scientists have not fully understood how these drugs work in the brain.

Tuesday, August 11 – An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks. Unlike injectable drugs such as Wegovy and Ozempic, aleniglipron is a small molecule that can be taken once daily with or without food and could potentially be produced more easily at scale.

Tuesday, August 11 – Chrissy Metz joins TODAY’s Jenna Bush Hager and Sheinelle Jones to talk about her journey with GLP-1s and becoming a spokesperson for Ro. She opens up about struggling with her weight as a child, dealing with “food noise,” and making healthy changes to her lifestyle. She shares how GLP-1s have improved her life and says she “wouldn’t be able to do 8 shows a week” without them. Then, she talks about having a supportive partner and the 10 year anniversary of “This Is Us.”

Monday, August 10 – GLP-1 medications may help lower fragility-related fracture risk in people with type 2 diabetes. OLEKSANDRA TROIAN · Moment/Getty

A new study found that GLP-1 medications may help reduce the risk of fragility fractures in people with type 2 diabetes.

Sunday, August 9 – A heads-up to anyone on medications like Ozempic, Wegovy, Zepbound and more.View Entire Post ›

Sunday, August 9 – Eli Lilly and Co. fired off a round of lawsuits in Delaware federal court seeking to block generic versions of its tirzepatide weight loss and diabetes medications, targeting Sandoz, MSN Laboratories and others.

Friday, August 7 – In our series “The Cost of Denial” NBC News’ Liz Kreutz reports on the debate over when and how to cover popular weight loss drugs, especially after a patient sheds the pounds. Should GLP-1s be covered as maintenance drugs?

Friday, August 7 – A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.

Friday, August 7 – Another quarter, another battle on the GLP-1 front. This time, the winner seems to be Eli Lilly and Co., which reported a 48% increase in second-quarter sales driven primarily by tirzepatide drugs Zepbound and Mounjaro for diabetes and obesity drugs, blowing past analyst expectations. Though also disclosing impressive numbers, Novo Nordisk A/S found investors focusing on sales of its pill version of Wegovy (semaglutide), which fell short of analyst estimates for the three months ending June 30.

Friday, August 7 – A Texas federal judge has denied Revive Rx’s bid to end Eli Lilly and Co.’s remaining unfair competition claims over the compounding pharmacy’s sales of allegedly unapproved tirzepatide weight loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive’s argument that compounded drugs fall outside state “new drug” laws.

Thursday, August 6 – Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.

Thursday, August 6 – Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities.

Thursday, August 6 – As the use of GLP-1 and other incretin-based medications for obesity continues to grow worldwide, researchers at Marshall University have contributed to an international effort to address one of medicine’s most pressing unanswered questions: How should these medications be used by women before, during and after pregnancy?

Thursday, August 6 – Novo Nordisk’s shares fell 6% on Tuesday afternoon after its second quarter earnings report showed a slight miss for the Wegovy pill vs. consensus.

Wednesday, August 5 – (MedPage Today) — The American Diabetes Association (ADA) asked for patience as its Audit and Governance Committee reviews the incident at this year’s annual meeting — when five prominent experts were removed by police — and prepares recommendations…

Wednesday, August 5 – (MedPage Today) — Retatrutide Access Expanded

Wednesday, August 5 – A heads-up to anyone on medications like Ozempic, Wegovy, Zepbound and more.

Tuesday, August 4 – (MedPage Today) — GLP-1 Temporal Hollowing

Tuesday, August 4 – (MedPage Today) — Bariatric surgery has long been considered the gold standard for treating obesity. However, with weight-loss medications like GLP-1 receptor agonists skyrocketing in popularity, fewer patients are choosing surgery.
According…

Monday, August 3 – As food becomes less stimulating, GLP-1 users are gravitating toward this instead.View Entire Post ›

Sunday, August 2 – (MedPage Today) — Note that some links may require registration or subscription.
Ahman Green, 49, a four-time NFL Pro Bowl running back and the Green Bay Packers’ career rushing leader, has Parkinson’s disease. (AP)
In other NFL news, former…

Friday, July 31 – This is the reality TikTok won’t show you.